San Francisco-based WearLinq says the acquisition will help its six-lead ECG technology reach more heart patients throughout the United States.   

With cardiovascular disease on the rise, clinicians and health systems continue to look for ways to deliver high-quality care that is both timely and cost-effective.

The new algorithm from Implicity evaluates implantable device data and monitors patients for changes that suggest they could experience severe heart failure symptoms in the near future. It was designed to alert clinicians up to weeks in advance.

Only radiology is associated with more FDA-cleared AI algorithms than cardiology, according to new federal data. 

JR Finkelmeier has more than 20 years of experience in the healthcare and medical device industries.

Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically active.

Biga, who originally trained as a nurse, specializes in the business side of cardiology. She also emphasized the increasing importance of AI and other new technologies. 

The portable device uses HeartBeam's patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthetic 12-lead ECG.